Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 14, 2024
Daily News
February 14, 2024
- AMED Chief Eyes 20-30% Team Expansion by FY2029
February 14, 2024
- CureApp’s Therapeutic App Makes Mark in PIII Alcohol Reduction Study
February 14, 2024
- Ono, Shattuck Ink Drug Discovery Collab on Bifunctional Fusion Proteins
February 14, 2024
- Takeda Earns US Nod for Oral EoE Drug after Resubmission
February 14, 2024
- Sawai and Kaigen Submit Biz Improvement Plans to Osaka Govt
February 14, 2024
- MHLW to Review Pig Kidney Transplant Plan Including Ethical Issues: Minister
February 14, 2024
- Otsuka Cuts 2023 Profit Guidance after AD Agitation Trial Miss
February 14, 2024
- Otsuka’s AVP-786 Fails in PIII Alzheimer’s Agitation Study
February 14, 2024
- Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
February 14, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…